In CRC, Sato et al. have found that STOCK1S-50699 treatment could inhibit the interaction between WNK1/4 and the GID complex, leading to the reduced degradation of β-Catenin and enhanced oncogenic Wnt/β-Catenin signaling [94]. The gene discussed is WNK1; the disease is colorectal carcinoma.